Abstract:BackgroundOptimal immunosupression is crucial for transplant success. In orthohepatic transplants, blood target levels of tacrolimus, when coadministred with corticoids and mycophenolic acid, are between 6 and 10 ng/mL during the first three months post-transplant. Notwithstanding, achieving tacrolimus concentrations into this range may be tough because of factors such as liver function status, age, sex, drug-drug interactions, etc. In this way, pharmacogenetic testing of CYP3A5 and CYP3A4 genes have demonstrated to be useful in tacrolimus dosing optimization. Nonetheless, there is no evidence enough for pharmacogenetic based adjusting in liver transplant, specially if receptor and graft's genotypes differ in these loci .The aim of the present study is to find out how the receptor and donor genotypes in CYP3A5 and CYP3A4 genes affect tacrolimus pharmacokinetics.MethodsGenotypic profiling of 108 receptor-donor's pairs biopsies gathered from patients who were underwent hepatic transplant from 2012 to 2019 were carried out using Taqman ® OpenArrayTM PGx Express 120 panel (ThermoFisherTM). We focused on CYP3A5 *3, *6 and *7; and CYP3A4 *1B, *3 and *22 alleles. Next to pharmacogenetic testing, each patient was classified as very poor, poor, intermediate, rapid or ultrarapid metabolizer according to their own genotype, graft's genotype or both of them. Patient's initial dose, at seven days after treatment start and after discharge of tacrolimus and their trough concentrations (C 0 ) were collected from their electronic health records.Tacrolimus levels were measured by affinity chrome-mediated immunoassay. C 0 was normalized by weight-adjusted dosage (C/D ratio); then, median C/D ratios between different metabolic profiles were compared through Kruskal-Wallis test.ResultsWhen patients were classified based on donor's genotype isolated or combined with receptor's genotype, lower C/D ratios were found as metabolizer ability increases (p=0.045 for donors and p=0.027 for combined genotypes, respectively). No statistically differences were found for C/D ratios at seven days and discharge, though that differences were almost significant for donor's genotypes (p=0.06 in both cases).ConclusionsThese results show that previous information about both patient's and specially donor's CYP genes genotype may improve initial immunosupression and avoid tacrolimus induced toxicity. Pharmacogenetics has been currently proposed as a guide for tacrolimus treatment of some solid organ transplants as kidney transplanted patients. Better understanding of how receptor and donor's CYP genotype affects its pharmacokinetics, along with liver's damage markers and other genetic polymorphisms will allow clinicians, in the era of personalized medicine, to improve immunosupressive management.

Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus

TLR10 Genotypes Affect Long-Term Graft Function in Tacrolimus-Treated Solid Organ Transplant Recipients.

Polymorphisms of Tumor Necrosis Factor-Α, Interleukin-10, Cytochrome P450 3A5 and ABCB1 in Chinese Liver Transplant Patients Treated with Immunosuppressant Tacrolimus

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

Population Pharmacokinetics of Tacrolimus and CYP3A5, MDR1 and IL-10 Polymorphisms in Adult Liver Transplant Patients

Impact of genetic polymorphisms on tacrolimus concentrations and intra-individual variability in recipients of heart transplants during the early post-heart transplantation period

Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients

Stepwise Regression Analysis of the Determinants of Blood Tacrolimus Concentrations in Chinese Patients with Liver Transplant

Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population.

Impact of Multidrug Resistance 1 Gene Polymorphism on Tacrolimus Dose and Concentration-to-dose Ratio in Chinese Liver Transplantation Recipients.

Association of Donor Small Ubiquitin-Like Modifier 4 Rs237025 Genetic Variant with Tacrolimus Elimination in the Early Period after Liver Transplantation.

Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients

Polymorphisms in Stat4 Increase the Risk of Acute Renal Allograft Rejection in the Chinese Population

CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients

Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Genetic factors underlying tacrolimus intolerance after liver transplantation

Influence Of Cyp3a5 Gene Polymorphisms Of Donor Rather Than Recipient To Tacrolimus Individual Dose Requirement In Liver Transplantation

B-222 Receptor-donor CYP3A5 and CYP3A4 genotype testing in liver transplant patients and its influence in tacrolimus blood levels: a retrospective study

Pharmacogenomics Analysis in Chinese Pediatric Liver Transplantation Patients with Renal Toxicity Induced by Tacrolimus

Tacrolimus Dose Requirement In Relation To Donor And Recipient Abcb1 And Cyp3a5 Gene Polymorphisms In Chinese Liver Transplant Patients